The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...

The University of Iowa study is analyzing the period between breast cancer diagnosis and treatment, when many patients feel ...

The typical treatment for estrogen receptor positive (ER+) breast cancer involves surgery and years of hormone therapy that ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Nov. 25, 2024 — Tamoxifen is a common and important treatment to prevent breast cancer from recurring. A new study shows that variation in a patient's gut microbiome can impact how effective the ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...